Forschungszentrum für Immuntherapie (FZI)
Forschungsschwerpunkt / Johannes Gutenberg-Universität Mainz
Gaertner, Yvonne; Bitar, Lynn; Zipp, Frauke et al.
Interleukin-4 as a therapeutic targetPHARMACOLOGY & THERAPEUTICS. Bd. 242. 2023
Kotsiliti, Elena; Leone, Valentina; Schuehle, Svenja et al.
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signallingJOURNAL OF HEPATOLOGY. Bd. 79. H. 2. 2023 S. 296-+
Teschner, David; Gomez-Zepeda, David; Declercq, Arthur et al.
Ionmob: a Python package for prediction of peptide collisional cross-section valuesBIOINFORMATICS. Bd. 39. H. 9. 2023
Brand, Anna; Hovav, Avi-Hai; Clausen, Bjorn E.
Langerhans cells in the skin and oral mucosa: Brothers in arms?EUROPEAN JOURNAL OF IMMUNOLOGY. 2023
Harroud, Adil; Stridh, Pernilla J.; McCauley, Jacob H. et al.
Locus for severity implicates CNS resilience in progression of multiple sclerosisNATURE. Bd. 619. H. 7969. 2023 S. 329-331
Schraad, Muriel; Uphaus, Timo; Bittner, Stefan et al.
Long-term observation of SARS-CoV-2 vaccination response in multiple sclerosis in a real world scenarioMULTIPLE SCLEROSIS JOURNAL. Bd. 29. 2023 S. 619-619
Schroers, Barbara; Hos, Brett J.; Yildiz, Ikra G. et al.
MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expressionFRONTIERS IN IMMUNOLOGY. Bd. 14. 2023
Rausch, Johanna; Dzama, Margarita M.; Dolgikh, Nadezda et al.
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclaxHAEMATOLOGICA. Bd. 108. H. 10. 2023 S. 2837-2843
Santisteban, Monica M.; Schaeffer, Samantha; Anfray, Antoine et al.
Meningeal interleukin-17-producing T cells mediate cognitive impairment in a mouse model of salt-sensitive hypertensionNATURE NEUROSCIENCE. 2023
Fleischer, Vinzenz; Brummer, Tobias; Muthuraman, Muthuraman et al.
Multimodal biomarker combinations predict disease activity and progression over 4 years in early multiple sclerosisMULTIPLE SCLEROSIS JOURNAL. Bd. 29. 2023 S. 322-323